On January 29, Wisdom Buds announced that its new drug information database officially launched the standard version for biomedical small and medium-sized enterprises, with an annual fee of only 16,800 yuan. Compared with the annual fee of more than 100,000 yuan for similar products in the market, it is about equivalent to only 2% of the cost, and you can have the same rich functions.
Pei Lidong, Global Director of Biopharmaceutical Products of Wisdom Buds, said: "Biomedicine is the first and most cooperative service industry of Wisdom Buds. We deeply understand the huge challenges faced by innovative pharmaceutical companies in recent years, and hope that through this product upgrade and iteration, the first-class system can further adapt to the needs of pharmaceutical companies of different scales, reduce the cost burden of pharmaceutical companies from practical actions, and improve R&D efficiency. We firmly support China's drug innovation, promote the innovation and development of the industry, and look forward to working with the industry towards the spring of new drug research and development." ”
Break the best barriers and help the development of innovative drugs in China.
Since the 2015 pharmaceutical reform, China's biopharmaceutical industry has developed rapidly, and remarkable results have been achieved in just a few years. New technologies such as monoclonal antibodies, ADCs, and cells** have quickly filled the gap and flattened the gap with developed countries in Europe and the United States. The gap in emerging fields such as nucleic acid technology, PROTAC, gene editing, and artificial intelligence pharmaceuticals is also narrowing, and some have even reached global synchronization. China's capital markets have also shown unprecedented enthusiasm for the biopharma industry, with the valuation of related assets being among the most expensive in the world in both primary and secondary markets, providing ample funding for innovation.
However, since mid-2021, China's biomedical financing has declined sharply, and the industry is facing a "capital winter". According to statistics, in the past three years, the market value of China's ** biomedical sector has evaporated nearly 600 billion yuan. The direct impact of the "cold winter" is that the new drug R&D pipeline without financing is unsustainable, which will further lead to a decrease in China's innovative drug achievements in the next few years.
In order to meet the different needs of pharmaceutical companies of different sizes for tools or data services, Wisdom Buds New Drug Intelligence Library has created a more complete product matrix, and is committed to empowering more Chinese innovative drug companies with professional data and products.
1.Standard Edition: Low-cost access to high-quality new drug development data.
The Standard Edition is suitable for small and medium-sized enterprise users or university teachers and students to complete in-depth research, track competition and potential projects, and export data for summary analysis. Compared with the Basic Edition, the Standard Edition will have no upper limit on the number of searches and search results, support data export, and open access to data from sections such as patents, drug transactions, and clinical results. In addition, users can experience more advanced features such as retrieval of ADC drug antibodies, linkers, and payloads. The standard version is priced at 16,800 yuan per year, which can help small and medium-sized enterprises save 8% of the cost of new drug R&D data and information compared with similar products on the market.
2.Professional Edition: More professional and intelligent, supporting large-scale data management.
The professional version is suitable for multi-pipeline enterprise users, consulting firms, or university teachers and students, providing them with more intelligent analysis and storage tools, and supporting data management. The Professional Edition includes all the features of the Standard Edition, but also adds some new features designed to provide enterprise users with a comprehensive solution, such as workspaces, knowledge graphs, unlimited custom analytics, and more data export to meet the needs of large data retrieval and export. At the same time, to facilitate enterprise account management, this version supports IP segment access and domain name access.
Figure: Comparison of the three versions of the new drug information database of Wisdom Buds.
Since March 2022, Wisdom Buds announced that the basic version of the new drug intelligence database will be opened to users in the global biopharmaceutical industry for free, and the new drug information database has served more than 330,000 institutions, attracting nearly 200,000 users to register and use. After this product upgrade, the basic version of the new drug information database will continue to be free and open to meet the needs of individual users or university teachers and students to complete preliminary research or low-frequency project research.
Comprehensive, accurate and real-time data update system.
Wisdom Buds New Drug Information Library is committed to providing comprehensive, accurate, real-time and standardized full life cycle data services for the entire industry chain of the biopharmaceutical industry. In the past year, two new sub-databases of clinical results and drug transactions have been added to the new drug information database, which now covers more than 140,000 clinical results and more than 10,000 drug transaction information.
Figure: Data range of Wisdom Buds' new drug intelligence database.
The New Drug Intelligence Database's data** includes data from global drug evaluation and clinical institutions, news**, official corporate R&D pipelines, global patents, and life sciences-related literature. Take the data update of the drug library ** as an example: 77% of the data from clinical trial institutions, 12% from drug evaluation institutions, 7% from corporate official websites, and 4% from news and literature.
Figure: Proportion of drug library data updates**.
With the information processing mechanism of "global big data AI real-time mining + pharmaceutical expert team verification", the new drug information database has established a real-time data update system on a global scale, especially in the data coverage and accuracy of drug research and development pipelines, clinical trial results, and drug patents.
Drug Library: As of the end of December 2023, the new drug intelligence database currently covers 46,816 drugs under development, while the number of drugs under development in Friend C is 42,034, and the number of drugs under development in Friend P is 43,332.
Clinical trial results database: At present, the new drug intelligence database mainly evaluates 8,582 drugs, including 4,853 indications and 1,758 targets. Compared with Youshang I and Youshang P, the amount of clinical outcome data of Wisdom Buds is far ahead.
Figure: Data coverage of clinical trial results.
As of the end of January 2024, the total number of clinical outcome data in the Wisdom Buds New Drug Intelligence Library has exceeded 140,000, covering 16 major disease areas such as tumors, immune system, musculoskeletal system, and respiratory system. Data sources cover 69 conference sources, PUBMED, FDA EMA tags, and other news sources over the past 20 years.
Figure: Disease domain distribution of clinical outcomes in the new drug information database.
Drug patent database: The new drug information database has covered more than 15.34 million patents, leading the industry in terms of overall accuracy and coverage of patents, total number of patents and number of receiving offices. On this basis, in order to facilitate users to quickly obtain various relationship label patents, the deeply processed relationship dimensions include target-patent relationship, indication-patent relationship, drug-sequence relationship, etc., among which the searchable number of searchable targets and patent relationships has exceeded 10.6 million, and the searchable number of indications and patent relationships has exceeded 25 million. In addition, the New Drug Intelligence Database also extracts commonly used dosage forms in drug patents, which currently covers more than 1.05 million patents.
AI-empowered to efficiently retrieve and analyze data.
Based on more than ten years of AI technology precipitation, Wisdom Buds New Drug Information Library has developed a number of intelligent functions, such as knowledge graph, AI assistant, etc., which will effectively improve the efficiency of users in retrieving and analyzing new drug data.
Compared with traditional databases, the knowledge graph function can better express the relationship between entities, help users freely explore the association between drugs, institutions, indications, and targets, and deeply optimize the user search experience. Taking the target CD19 as an example, the knowledge graph intuitively shows the common indications and R&D stages of the two drugs, namely axileucel and rikimarencel. In addition, the knowledge graph also allows users to explore potential indications for the target, find possible cooperative institutions, etc.
Figure: Schematic diagram of the knowledge graph function of the new drug information database of Wisdom Buds.
At the same time, the new drug information database has a built-in AI assistant developed by Wisdom Buds, which is designed to help users translate, explain and summarize the product with one click. For example, based on the search results, click the Page Summary button of the AI assistant, and it will automatically generate a summary report of the current page, making information integration one step faster.
Figure: Schematic diagram of the AI assistant function of the new drug information database of Wisdom Buds.
Wisdom Buds is committed to giving full play to its advantages in AI and data with the spirit of continuous innovation, creating efficient and intelligent biomedical information services, and will continue to polish its products in the future to build a more professional and comprehensive one-stop pharmaceutical big data service platform.
Attached: Entrance to the new drug information database.
Note: Although registration can also be done on the mobile terminal, it is recommended that you use the PC terminal for the best user experience.